Compare TRNO & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRNO | NUVL |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 7.1B |
| IPO Year | 2010 | 2021 |
| Metric | TRNO | NUVL |
|---|---|---|
| Price | $60.52 | $104.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 14 |
| Target Price | $65.08 | ★ $134.29 |
| AVG Volume (30 Days) | 642.0K | ★ 828.0K |
| Earning Date | 02-04-2026 | 10-30-2025 |
| Dividend Yield | ★ 3.39% | N/A |
| EPS Growth | ★ 75.67 | N/A |
| EPS | ★ 3.15 | N/A |
| Revenue | ★ $442,611,000.00 | N/A |
| Revenue This Year | $22.90 | N/A |
| Revenue Next Year | $10.30 | N/A |
| P/E Ratio | $19.50 | ★ N/A |
| Revenue Growth | ★ 21.13 | N/A |
| 52 Week Low | $48.18 | $55.54 |
| 52 Week High | $69.20 | $112.88 |
| Indicator | TRNO | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 44.97 | 51.87 |
| Support Level | $59.55 | $103.52 |
| Resistance Level | $62.97 | $107.99 |
| Average True Range (ATR) | 1.21 | 3.18 |
| MACD | -0.24 | -0.93 |
| Stochastic Oscillator | 23.63 | 10.43 |
Terreno Realty Corp is a real estate investment trust engaged in acquiring, owning, and operating industrial real estate in six coastal U.S. markets: Los Angeles, Northern New Jersey/New York City, San Francisco Bay Area, Seattle, Miami, and Washington, D.C. The company invests in several types of industrial real estate, including warehouse/distribution, flex (including light industrial and research and development), transshipment, and improved land.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.